Stocktoria

Maze Therapeutics, Inc. MAZE

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2025-01-31

Maze Therapeutics, Inc. statistics & valuation

Market cap$1.6B
P / B4.4×
Return on equity-36.9%
Return on capital-38.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20242025
Operating margin (%)
34.40% 20242025
Return on equity (%)
-36.90% 20242025
Shares outstanding
2.7M 49.3M 20242025
Net debt ($)
20242025
Share buybacks ($)
20242025
Return on assets (%)
21.70% -33.00% 20242025
Free cash flow margin (%)
44.70% 20242025
Debt / equity (×)
20242025
EPS ($)
$1.25 -$3.05 20242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024
Operating margin—34.4%
Net margin—31.2%
FCF margin—44.7%
Return on assets-33.0%21.7%
Return on equity-36.9%-16.8%
Current ratio15.509.76

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.